Search research articles
Contact Us
Filters
Showing results (101-110 of 133) with videos related to
Page
of 14
Sort By:
British Journal of Cancer
|
May 14, 2009
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
E Vasile, G Masi, L Fornaro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2013
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
F Loupakis, C Cremolini, L Salvatore, et al.
ESMO Gastrointestinal Oncology
|
April 17, 2026
Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study
Y J Kim, P Merle, R S Finn, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Concordance of PD-L1 status in primary gastroesophageal adenocarcinoma and matched peritoneal metastases: a single institution study
V Massa, F Signorini, F Salani, et al.
British Journal of Cancer
|
August 30, 2008
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
F Graziano, A Ruzzo, F Loupakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 14, 2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)
L Fornaro, S Lonardi, G Masi, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
August 4, 2015
Phylogenetic characterization of Central/Southern European lineage 2 West Nile virus: analysis of human outbreaks in Italy and Greece, 2013-2014
L Barzon, A Papa, E Lavezzo, et al.
ESMO Open
|
October 24, 2021
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
D Rossini, A Boccaccino, A Sbrana, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2015
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
G Masi, L Salvatore, L Boni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
D Santini, B Vincenzi, R Addeo, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 133) with videos related to
Sort By:
Page
of 14
British Journal of Cancer
|
May 14, 2009
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
E Vasile, G Masi, L Fornaro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2013
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
F Loupakis, C Cremolini, L Salvatore, et al.
ESMO Gastrointestinal Oncology
|
April 17, 2026
Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study
Y J Kim, P Merle, R S Finn, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Concordance of PD-L1 status in primary gastroesophageal adenocarcinoma and matched peritoneal metastases: a single institution study
V Massa, F Signorini, F Salani, et al.
British Journal of Cancer
|
August 30, 2008
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
F Graziano, A Ruzzo, F Loupakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 14, 2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)
L Fornaro, S Lonardi, G Masi, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
August 4, 2015
Phylogenetic characterization of Central/Southern European lineage 2 West Nile virus: analysis of human outbreaks in Italy and Greece, 2013-2014
L Barzon, A Papa, E Lavezzo, et al.
ESMO Open
|
October 24, 2021
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
D Rossini, A Boccaccino, A Sbrana, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2015
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
G Masi, L Salvatore, L Boni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
D Santini, B Vincenzi, R Addeo, et al.
Page
of 14